Clinical Trials Browser

Withdrawn × INDUSTRY × sargramostim × Clear all

NCT05284214 2023-09-15

SALIENT

Phase 2 Withdrawn

Other solid neoplasm

Solid Tumor

NCT02520102 2017-04-20

Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia

Phase 2 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute